ReNeuron Group (RENE) RNS Announcements

Add to Alert list
Date Time Source Announcement
30 Mar 2012 07:00 AM
RNS
Issue of Ordinary Shares
27 Mar 2012 07:00 AM
RNS
Exercise of Warrants
20 Jan 2012 09:36 AM
RNS
Notification of Major Interest in Shares
17 Jan 2012 07:00 AM
RNS
Webcast and content of Stem Cell Technical Seminar
11 Jan 2012 12:20 PM
RNS
Change of Adviser and Broker
11 Jan 2012 07:00 AM
RNS
Stability of lead stem cell line
09 Jan 2012 10:00 AM
RNS
ReNeuron to present at US healthcare conference
09 Jan 2012 07:00 AM
RNS
Notification of Stem Cell Technical Seminar
03 Jan 2012 07:00 AM
RNS
Data confirms pre-clinical efficacy of ReN001
19 Dec 2011 04:41 PM
RNS
Second Price Monitoring Extn
19 Dec 2011 04:35 PM
RNS
Price Monitoring Extension
06 Dec 2011 10:00 AM
RNS
Welcomes UK Government Life Sciences Strategy
30 Nov 2011 04:35 PM
RNS
Price Monitoring Extension
28 Nov 2011 07:00 AM
RNS
Stroke Update
28 Nov 2011 07:00 AM
RNS
Interim Results
09 Nov 2011 07:00 AM
RNS
Stroke clinical trial update & notice of results
03 Nov 2011 02:54 PM
RNS
Notification of Major Interest in Shares
01 Nov 2011 02:13 PM
RNS
Notification of Interest in Shares
31 Oct 2011 10:42 AM
RNS
Notification of Major Interest in Shares
10 Oct 2011 07:00 AM
RNS
ReNeuron to present at Stem Cell Conference
22 Sep 2011 12:53 PM
RNS
Directors' Interest in Shares and Share Options
22 Sep 2011 12:48 PM
RNS
Directors' Interest in Shares
15 Sep 2011 10:45 AM
RNS
Results of 2011 Annual General Meeting
15 Sep 2011 07:00 AM
RNS
AGM Trading Update
13 Sep 2011 07:00 AM
RNS
ReNeuron gives update on stroke clinical trial
01 Sep 2011 04:35 PM
RNS
Price Monitoring Extension
01 Sep 2011 07:00 AM
RNS
ReNeuron receives DSMB clearance
29 Jul 2011 03:24 PM
RNS
Annual Report and Accounts and Notice of AGM
20 Jul 2011 07:00 AM
RNS
Board Appointments
05 Jul 2011 07:00 AM
RNS
Contract with Angel Biotechnology Holdings plc
30 Jun 2011 07:00 AM
RNS
Preliminary Results
24 Jun 2011 02:56 PM
RNS
ReNeuron launches new website
16 Jun 2011 07:00 AM
RNS
License agreement with US eye research institute
01 Jun 2011 09:43 AM
RNS
Block Listing Six Monthly Review
27 May 2011 07:00 AM
RNS
Notice of Results and Stroke Clinical Trial Update
18 May 2011 07:00 AM
RNS
ReNeuron to participate in stem cell conference
11 May 2011 02:30 PM
RNS
Comment re: Government Initiative
28 Apr 2011 12:22 PM
RNS
EU legal opinion
15 Apr 2011 10:37 AM
RNS
Anti-depressants make new brain cells
08 Apr 2011 07:00 AM
RNS
Manufacturing Agreement
24 Mar 2011 07:00 AM
RNS
ReNeuron to benefit from Budget
04 Mar 2011 07:00 AM
RNS
UK stem cell and life science conferences
03 Mar 2011 10:10 AM
RNS
ReNeuron gives update on stroke clinical trial
31 Jan 2011 10:00 AM
RNS
Trial leader to speak at UK p
28 Jan 2011 07:00 AM
RNS
Settlement with Neuralstem, I
10 Jan 2011 02:18 PM
RNS
TR-1 Notification of major in
10 Jan 2011 07:00 AM
RNS
TR-1 Notification of major in
07 Jan 2011 07:00 AM
RNS
TR-1: Notification of major i
04 Jan 2011 07:00 AM
RNS
Major Interest in Shares
29 Dec 2010 11:34 AM
RNS
RESULT OF GENERAL MEETING & T

ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

It listed on AIM in 2006 under the ticker RENE.

UK 100

Latest directors dealings